We are live on ! Find out more
PHS

PFM Health Sciences Portfolio holdings

AUM $1.1B
1-Year Est. Return 57.92%
This Fund
S&P 500
This Quarter Est. Return
+0.34%
1 Year Est. Return
+57.92%
3 Year Est. Return
+183.93%
5 Year Est. Return
+283%
10 Year Est. Return
+2,507.28%
AUM
$2.02B
AUM Growth
-$106M
Cap. Flow
-$45.5M
Cap. Flow %
-2.25%
Top 10 Hldgs %
46.17%
Holding
96
New
10
Increased
23
Reduced
12
Closed
18

Top Buys

Rank Stock Value
1
UNH icon
UnitedHealth
UNH
+$24.5M
2
AMGN icon
Amgen
AMGN
+$23.8M
3
SYK icon
Stryker
SYK
+$20.1M
4
JNJ icon
Johnson & Johnson
JNJ
+$19.2M
5
BSX icon
Boston Scientific
BSX
+$12.8M

Top Sells

Rank Stock Value
1
LEGN icon
Legend Biotech
LEGN
+$41.2M
2
ZBH icon
Zimmer Biomet
ZBH
+$39.6M
3
AVTR icon
Avantor
AVTR
+$34.3M
4
VEEV icon
Veeva Systems
VEEV
+$27.5M
5
WST icon
West Pharmaceutical
WST
+$20.3M

Sector Composition

Rank Sector Weight
1 Healthcare 88.57%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LLY icon
1
Eli Lilly
LLY
$1.05T
$270M 13.38%
298,643
– –
CYTK icon
2
Cytokinetics
CYTK
$11B
$95.2M 4.71%
1,757,192
– –
QQQ icon
3
CALL
Invesco QQQ Trust
QQQ
$471B
$89.8M 4.44%
+187,400
New +$84.3M
THC icon
4
Tenet Healthcare
THC
$16.7B
$78.4M 3.88%
589,409
– –
MRK icon
5
Merck
MRK
$312B
$73.8M 3.65%
596,261
– –
VRTX icon
6
Vertex Pharmaceuticals
VRTX
$122B
$69.8M 3.45%
148,852
– –
ABBV icon
7
AbbVie
ABBV
$452B
$69.3M 3.43%
403,861
– –
EW icon
8
Edwards Lifesciences
EW
$48.9B
$68.4M 3.38%
740,260
– –
ISRG icon
9
Intuitive Surgical
ISRG
$124B
$61.1M 3.02%
137,327
+26,290
+24% +$10.5M
MCK icon
10
McKesson
MCK
$97.3B
$56.9M 2.82%
97,498
– –
XBI icon
11
CALL
State Street SPDR S&P Biotech ETF
XBI
$10.4B
$55.1M 2.73%
+594,500
New +$53.3M
HUM icon
12
Humana
HUM
$47.8B
$46.8M 2.32%
125,340
– –
HCA icon
13
HCA Healthcare
HCA
$82.8B
$40.1M 1.98%
124,840
– –
CNC icon
14
Centene
CNC
$32.5B
$39.7M 1.96%
598,513
– –
UHS icon
15
Universal Health Services
UHS
$9.08B
$39.6M 1.96%
213,983
– –
SYK icon
16
Stryker
SYK
$121B
$38.9M 1.92%
114,297
+59,205
+107% +$20.1M
AXSM icon
17
Axsome Therapeutics
AXSM
$12.2B
$37.6M 1.86%
467,427
– –
ARGX icon
18
argenx
ARGX
$54.7B
$37.3M 1.85%
86,832
– –
ICLR icon
19
Icon
ICLR
$12.8B
$36.5M 1.81%
116,532
+806
+0.7% +$253K
UNH icon
20
UnitedHealth
UNH
$396B
$35.4M 1.75%
69,438
+50,077
+259% +$24.5M
TMO icon
21
Thermo Fisher Scientific
TMO
$195B
$35.2M 1.74%
63,650
+5,612
+10% +$3.22M
PEN icon
22
Penumbra
PEN
$12.5B
$33.3M 1.65%
185,111
+29,325
+19% +$5.85M
DHR icon
23
Danaher
DHR
$127B
$31.4M 1.55%
125,515
– –
BDX icon
24
Becton Dickinson
BDX
$42.6B
$30.7M 1.52%
131,378
-40,174
-23% -$9.46M
ELV icon
25
Elevance Health
ELV
$82.9B
$29.9M 1.48%
55,250
– –
1
2 3 4

Similar funds

DAM
Delta Asset Management Memphis, Tennessee $1.1B AUM 14.89% 1-Year Est. Return
MAM
Mark Asset Management New York $1.1B AUM 43.79% 1-Year Est. Return
CPRC
Consolidated Portfolio Review Corp Woodbury, New York $1.1B AUM 8.96% 1-Year Est. Return
AWP
Abacus Wealth Partners Santa Monica, California $1.1B AUM 14.74% 1-Year Est. Return
LCM
Legato Capital Management San Francisco, California $1.1B AUM 61.65% 1-Year Est. Return
PRS
Pinkerton Retirement Specialists Coeur D Alene, Idaho $1.1B AUM 30.57% 1-Year Est. Return
DAM
DLD Asset Management New York $1.1B AUM 4.68% 1-Year Est. Return
KCM
Khrom Capital Management Miami Beach, Florida $1.09B AUM 14.82% 1-Year Est. Return

PFM Health Sciences's Q2 2024 Portfolio in Review

As of Q2 2024, PFM Health Sciences held 96 positions worth $2.02B, down 5% from $2.13B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

PFM Health Sciences's Q2 2024 filing shows 10 new, 23 increased, 12 reduced and 18 closed positions. Its largest new stake was Amgen: 81,034 shares worth $25.3M. The largest sale was Legend Biotech, an estimated $41.2M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, down from 90% a quarter earlier.

  • PFM Health Sciences's largest Q2 2024 buy was Amgen: 81,034 shares worth $25.3M.
  • PFM Health Sciences added most to UnitedHealth in Q2 2024, an estimated $24.5M increase.
  • PFM Health Sciences's biggest Q2 2024 reduction was Becton Dickinson, cutting an estimated $9.46M.
  • PFM Health Sciences fully exited Legend Biotech in Q2 2024, selling an estimated $41.2M.
  • PFM Health Sciences's ten largest holdings make up 46% of its $2.02B portfolio in Q2 2024.
  • PFM Health Sciences opened 10 new positions and closed 18 in Q2 2024.
  • PFM Health Sciences's portfolio value fell 5% quarter-over-quarter to $2.02B.

Based on PFM Health Sciences's 13F filing for Q2 2024, filed 14 Aug 2024.